BIOLEGEND INC

10x Genomics said key Scale Biosciences products will remain on the market and that the company will continue participating in research programs such as the 100 Million Cell Challenge and the Billion Cells Project through the Chan Zuckerberg Initiative. \n 10x Genomics is stepping up to buy Scale Biosciences and its single-cell profiling solutions, with plans to implement them within the company’s Chromium platform. The deal for the recent Fierce Medtech Fierce 15 winner includes $30 million in upfront cash and stock plus undisclosed milestone payments.Scale Bio’s massively parallel tagging technology, dubbed Quantum Barcoding, allows researchers to pool together samples during processing while still labeling each transcript in the cell. Using a 96-well plate containing thousands of microwells, the approach can enable the sequencing of millions of cells at a time without extra specialized equipment. 10x said key Scale products will remain on the market and that the company will continue participating in research programs such as the 100 Million Cell Challenge and the Billion Cells Project through the Chan Zuckerberg Initiative. Earlier this year, Scale began shipping its RNA analysis kits, which aim to cost less than one cent per cell. And, in 2024, the company paired up with Revvity’s BioLegend business to launch a single-cell protein solution to help identify rare cell subtypes.“At 10x, we\'re relentlessly innovating to build a world where single cell analysis is routine, accessible, and scalable at levels previously unimaginable,” 10x Genomics CEO Serge Saxonov said in a statement.  “This acquisition is a step towards that vision—reflecting our commitment to accelerating adoption of single cell technologies,” Saxonov said. “By integrating Scale\'s inventions with 10x\'s global platform and innovation engine, we will broaden the capabilities and reach of existing and future products.”In addition, Scale\'s scientific co-founders are set to join 10x as advisors, including Garry Nolan, Ph.D., at Stanford University; Jay Shendure, M.D., Ph.D., and Cole Trapnell, Ph.D., at the University of Washington; and the company’s chief scientific officer, Frank Steemers, Ph.D.“We are incredibly proud of what we\'ve built at Scale and its impact advancing biological understanding in single cell analysis. Our integration with 10x will accelerate the adoption of our technology, helping it reach new customers and transformative emerging applications,” said Scale President and CEO Giovanna Prout. “We look forward to 10x building on our pioneering work and supporting a broader global customer base that will drive the next wave of biological discovery.”10x Genomics also posted its second-quarter earnings this week, totaling $172.9 million in revenue—however, that includes the receipt of $27.3 million through a patent litigation suit settled with Bruker earlier this year, following the latter’s acquisition of NanoString. Minus that, 10x’s sales amounted to $145.6 million, for a 5% decrease compared to the same period in 2024. Net income, however, reached $34.5 million versus a net loss of $37.9 million last year. The company said those figures also included $4 million from customers in China looking to make their purchases early before new tariffs took effect. “The second quarter unfolded largely as anticipated,” Saxonov said in a statement. “Amid continued uncertainty in the funding environment, we\'re encouraged by the resilience of our business and the dedication of our team. We\'re focused on disciplined execution, and remain confident in the strength of our technology, the momentum behind our platforms and the significant long-term opportunity in front of us.”

CAMBRIDGE, England--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the appointment of William J. Kullback to its Board of Directors as a Non-Executive Director (NED). Bill is a seasoned executive bringing extensive financial experience from large life science tool manufacturers to Nuclera’s leadership team. He joins the board at a crucial time for Nuclera as the company continues its global commercial expansion strategy following a successful $75 million series C close1. Dr Michael Chen, CEO and co-founder, Nuclera, commented: “I am pleased to welcome Bill to the Nuclera board. His distinguished career and financial expertise will be instrumental as we push forward with our growth strategy in line with our commercial goals. He added: “Bill’s experience will be invaluable to Nuclera as we scale to address current challenges in protein production by bringing eProtein Discovery to even more researchers.” Since August 2023, Bill has held the position of CFO at Telesis Bio, a company specializing in automated synthesis technology for therapeutic discovery, during which time he oversaw the restructuring of operational expenses resulting in a ~70% decrease. He brings over 30 years of experience as a CFO, focusing on financial and manufacturing operations, mergers and acquisitions, and public markets across multiple publicly traded companies. Bill previously served as CFO at BioLegend Inc., a worldwide provider of antibodies and life science reagents, where he helped manage the company’s $5.25 billion sale to NYSE listed Revvity (previously PerkinElmer), the largest acquisition in Revvity’s history. Bill also negotiated and closed acquisitions and investments whilst CFO at NASDAQ listed medical device company, Lombard Medical, prior to its acquisition by Shanghai-based MicroPort Scientific Corporation. He has also held senior financial positions at a range of medical device and life science tools businesses during his career. Bill earned both his MBA and bachelor’s degree from the State University of New York at Buffalo. Bill Kullback, Non-Executive Board Director, Nuclera, added: “Nuclera’s eProtein Discovery has the potential to transform drug discovery workflows. The Company is at an exciting stage as it expands globally and I am looking forward to working with the team to support the Company’s growth and drive success at this pivotal stage in Nuclera’s development.” For more information about Nuclera’s eProtein Discovery system, please visit: https://www.nuclera.com/system/

在近几年，蛋白组学领域可以说是一片热火朝天的景象。技术的快速发展和资本的持续加码让这一行业的玩家们纷纷掀起了并购浪潮。随着市场格局逐渐明朗，巨头们通过战略收购不断扩张版图，同时也揭示出行业未来的发展方向。 （珞米AI小编为大家整理了全球蛋白组学500亿美元市场格局的各路玩家，涵盖试剂、前处理、设备、IVD、制药。关注公众号，回复“格局”即可获得完整资料。） 本文中，珞米AI小编带大家回顾2021-2024年间的11次重磅并购事件，看看这些交易背后隐藏着怎样的产业并购逻辑？并购逻辑 1：生命科学巨头的产业链整合1. PerkinElmer豪掷52.5亿美元拿下BioLegend 2021年9月，PerkinElmer以52.5亿美元的大手笔收购了BioLegend。这家公司拥有业内领先的抗体与试剂产品线，此次交易标志着PerkinElmer正式发力蛋白组学领域。 这笔交易被视为PerkinElmer的一次“豪赌”，但也为其开辟了一条新的增长赛道。从结果来看，这个赌注或许是非常值得的。 2. 丹纳赫24亿美元收入囊中：Abcam的产业价值几何？ 2023年8月，丹纳赫以24亿美元的价格完成了对Abcam的收购。Abcam拥有抗体、蛋白质和生化试剂等丰富的产品线，而这些产品的加入无疑将增强丹纳赫在蛋白组学市场中的竞争力。 Abcam在研究市场上的口碑一向不错，但进入“丹纳赫体系”后，或许将迎来更多“产业化”机会。我们拭目以待，看看这笔交易是否能帮助丹纳赫抢占更大的市场份额。 并购逻辑2：设备巨头的短板补齐3. Bruker锁定Biognosys：瞄准标志物验证和发现 2023年1月，Bruker再度出手，以1亿美元左右的价格收购了Biognosys 90%以上的股份。Biognosys的TrueDiscovery™等平台专注于蛋白质标志物的发现和验证，完美契合了Bruker的业务需求。 连续两年出手的Bruker展现了强烈的扩张欲望。可以预见，未来几年，这家公司在蛋白组学领域的技术积累将可能改变行业游戏规则。 4. 赛默飞31亿美元大手笔：锁定Olink核心技术 在2024年7月的一次“重量级交易”中，赛默飞以31亿美元的价格拿下了Olink 74%的股份。这家瑞典公司凭借独创的PEA技术成为蛋白组学领域的一颗明星。赛默飞的投资显然是看中了其在精准医学和高通量蛋白质分析中的潜力。 2023年赛默飞发布跨时代的产品Orbitrap Astral，紧接着12月又官宣收购非质谱蛋白组领先公司Olink，2024年6月又发布超多重靶向蛋白检测设备Stellar。赛默飞野心不小，稳拿全球蛋白组龙头老大的心思昭然若揭。 5. Bruker拿下NanoString：空间与数字蛋白组学的强强联合 2024年4月，Bruker以3.926亿美元完成了对NanoString Technologies的收购。这家以空间组学技术闻名的公司，开发了由Leroy Hood博士团队主导的数字分子编码技术。Bruker借此在数字蛋白组学与空间组学交叉领域迈出了一大步。 NanoString的技术对于Bruker来说无疑是一个强有力的补充。值得关注的是，空间组学和蛋白组学的结合是否会催生更多革命性的研究工具？答案很可能是肯定的。 并购逻辑 3：小明星牵手，优势互补6. Standard BioTools与SomaLogic的“优势互补” 2023年10月，Standard BioTools和SomaLogic宣布以全股方式合并。作为一家以SOMAmer技术闻名的公司，SomaLogic带来了高通量蛋白质组学分析的强大能力，而Standard BioTools则进一步扩大了产品组合。这次合并的估值超过10亿美元。 这桩交易可以看作是两个“志同道合”的公司在全球蛋白组学浪潮中的战略性结合。未来，如何真正实现“1+1>2”的效果，将是对双方管理层的一大考验。是“抱团取暖”，还是“优势互补”？还需要时间的考验。 7. Standard BioTools出手 Sengenics：精准抗体检测的下一步？ 2024年12月，Standard BioTools将目光投向了功能性蛋白组学公司Sengenics。作为业内公认的“抗体分析专家”，Sengenics的KRX™技术和覆盖1800+疾病相关标志物的i-OMe™ Discovery平台可以说是这次交易的核心亮点。通过这笔收购，Standard BioTools显然希望巩固其在精准医学和疾病诊断中的技术优势。 “技术为王”在这个领域的重要性，随着个性化医疗的需求不断攀升，能够提供高灵敏度和高通量检测的公司将成为巨头们争相竞逐的目标。 8. Vizgen与Ultivue合并：空间转录组牵手空间蛋白组 2024年10月，空间组学两大新锐Vizgen和Ultivue宣布合并，这一消息引起了业内广泛关注。作为空间基因组学和蛋白组学的技术先锋，两家公司合并后的协同效应无疑将大幅提升其市场竞争力。他们决定继续沿用“Vizgen”的品牌名称，或许是想以简洁有力的方式打响知名度。 这意味着有可能实际就是Vizgen收购了Ultivue。但是合并后，原Ultivue的CEO将担任新公司的CEO，而Vizgen的CEO则保留了董事会席位。 空间组学近年来风头正劲，但市场上的竞争者众多。这次合并可能是为了抱团“过冬”，同时也向外界传递了一个信号：这个赛道已经进入资源整合和技术集中化的阶段。9. CellCarta收购Precision Assays：靶向生物标志物检测的绝佳补充 2024年9月，CellCarta完成了对Precision Assays的收购，这一消息引起了精准医疗领域的广泛关注。Precision Assays以其在质谱靶向蛋白质检测和生物标志物定量领域的专长而闻名，而CellCarta则是全球领先的CRO提供商。CellCarta将Precision Assays的定量靶向蛋白质分析技术整合到其现有的服务中，进一步增强了其在药物开发和伴随诊断中的能力。 这笔收购看似低调，但实际上颇具战略意义。随着药物研发对高精度蛋白质定量分析的需求激增，CellCarta正以一种务实的方式为客户提供更全面的解决方案。而这种“小而精”的技术收购，或许正是未来市场整合的一种新趋势。 并购逻辑 4：IVD巨头的精准出击10. Exact Sciences小成本收购OmicEra：布局蛋白癌症早筛 2022年6月，Exact Sciences以1500万美元的价格完成了对OmicEra Diagnostics的收购。这一交易虽然规模不大，但OmicEra基于质谱的蛋白组标志物发现技术无疑为Exact的癌症早筛业务增添了新动力。 这笔“小而精”的收购体现了Exact Sciences的独到眼光。癌症早筛是未来医疗的风口，拥有质谱技术的加持，他们或许会走得更快、更远。11. Quanterix以7500万美元收购Emission 2024年12月，美国单分子免疫IVD开创公司Quanterix宣布以7500万美元的价格收购Emission。而后者正是给Quanterix的单分子检测平台Simoa提供核心免疫磁珠的公司。Simoa是目前阿兹海默症等神经类疾病多重蛋白检测的行业领导者。 Quanterix宣称他们已经对Emission的磁珠完成了性能验证，不仅可以用于自己平台的升级款，还可以为其他场景OEM免疫磁珠。 值得一提的是，Emission整个公司只有8个人，7000万美元被收购，人均875万美元。敲黑板啊同学们，还是要好好努力学习一个，书中自有黄金屋！以及颜如玉emm... 回顾2021-2024年间的这些并购事件，不难看出，行业巨头正通过资本与技术的双轮驱动塑造着蛋白组学领域的新生态。从精准医学到癌症早筛，再到空间组学和标志物发现，这一领域的发展潜力巨大。未来，随着AI技术的进一步在蛋白组学的渗透，我们或许会见证更多“不可思议”的新突破。 关于Nanomics珞米生命科技 珞米生命科技（Nanomics Biotech）致力于打造世界级的高通量蛋白组学标准化平台，以前所未有的方式发现多重蛋白标志物，从而引领新一代精准医学和前沿药物开发的创新浪潮。公司由国家级创新和创业领军人才创立，核心团队来自于芝加哥大学，技术研发团队占80%以上。公司目前已申报专利数十项，并获得国家级科技型中小企业称号。 珞米科技推出的Proteonano™平台，可以实现同时对1500-5000个血浆蛋白质进行检测，且丰度超越8个数量级，低丰度蛋白覆盖2000个信号通路，包括心脏代谢、免疫肿瘤、神经学、炎症因子等，直接助力科研、药企和精准医疗公司。 公司实验室占地面积1000平米试剂和实验室自动化机器人生产场地，并拥有一类医疗器械生产许可资质。实验室配备超多重高通量蛋白组平台50套，年处理样本量超过10万例。公司在神经类疾病生物标志物发现领域、心脏代谢疾病、和药物疗效评估方面成果斐然，已经和全国20个省份的顶级研究所和高校开展合作项目，以及与各大服务公司和创新药企建立长期合作关系。 Proteonano™平台现已开启全球招商，诚邀合作伙伴加盟，一起打开下一代蛋白质组学NGP超过500亿美元的市场。